Art. -Nr.: HY-135232

MMP-9-IN-1

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.82%
CAS. Nr.: 502887-71-0
Formel: C₁₆H₁₇F₂N₃O₃S
Molecular Weight:369.39

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

MMP-9-IN-1 Chemical Structure

CAS. Nr.: 502887-71-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs^[1].

IC₅₀ & Target^[1]

MMP-9

Alle MMP Isoform-spezifische Produkte anzeigen :

In Vitro

MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity^[1].
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

COS-1 monkey epithelial cell lines
Concentration:

100 μM
Incubation Time:

24 hours
Result:

Treatment did not cause notable cytotoxicity.

Cell Proliferation Assay^[1]

Cell Line:

HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9
Concentration:

10 μM
Incubation Time:

9 days
Result:

Significant inhibition of cell proliferation.

In Vivo

MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor^[1].
MMP-9-IN-1 inhibits cancer cell metastasis in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor^[1]
Dosage:

20 mg/kg
Administration:

Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:

Resulted in a profound delay in tumor growth.
Inhibited cancer cell metastasis.

Chemical Information

CAS. Nr. 502887-71-0
Appearance Solid
Molecular Weight 369.39
Formel C₁₆H₁₇F₂N₃O₃S
Color White to off-white
SMILES

O=C(NC1=CC=C(OC(F)F)C=C1)CSC2=NC(CCC)=CC(N2)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All WBCell Proliferation/Viability AssayIn Vivo Efficacy StudyCell Migration/Invasion AssayBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nat Commun

CRL3Keap1 E3 ligase facilitates ubiquitin-mediated degradation of oncogenic SRX to suppress colorectal cancer progression. [Abstract]

2024 Dec 3;15(1):10536. PMID: 39627198

MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]

Transwell assays were employed to evaluate the migration and invasion abilities of Keap1-knockdown HCT116 cells treated with 40 μM MMP9 inhibitor MMP-9-IN-1 for 48 h (n = 5). The cells were harvested for western blotting analysis.

MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]

Transwell assays were employed to evaluate the migration and invasion abilities of Keap1-knockdown HCT116 cells treated with 40 μM MMP9 inhibitor MMP-9-IN-1 for 48 h (n = 5). Representative images were captured. The scale bar was 200 μm.
J Immunother Cancer

EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion. [Abstract]

2024 Jun 17;12(6):e008375. PMID: 38886114
Cell Death Discov

ROS/MMP-9 mediated CS degradation in BMSC inhibits citric acid metabolism participating in the dual regulation of bone remodelling. [Abstract]

2024 Feb 14;10(1):77. PMID: 38355572

MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Feb 14;10(1):77. [Abstract]

Effect of MMP-9-IN-1 ( 0.1-10 µM; 24-72 h) on osteoblast proliferation.

MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Feb 14;10(1):77. [Abstract]

MMP-9-IN-1 (0.1-10 µM; 72 h) significantly inhibited MMP-9 activity in cells.
Eur J Pharmacol

HIF-1α/MMP-9 promotes spinal cord central sensitization in rats with bone cancer pain. [Abstract]

2023 Sep 5:954:175858. PMID: 37356787

MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Sep 5:954:175858. [Abstract]

MMP-9-IN-1 (20 mg/kg; i.g.; once every other day for a total of 5 administrations) significantly increased mechanical allodynia to Von Frey filaments, prolonged the latency of thermal hyperalgesia, and reduced spontaneous pain behaviors in rats with bone cancer pain (BCP).
J Cell Mol Med

PDX regulates inflammatory cell infiltration via resident macrophage in LPS-induced lung injury. [Abstract]

2020 Sep;24(18):10604-10614. PMID: 32735065
Biol Reprod

Collagen turnover during cervical remodeling involves both intracellular and extracellular collagen degradation pathways. [Abstract]

2025 Apr 13;112(4):709-727. PMID: 39823285
Int J Morphol

2023 Aug, 41(4):1152-1157.
Saarland University

2025.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 66.67 mg/mL (180.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7072 mL

13.5358 mL

27.0717 mL

5 mM

0.5414 mL

2.7072 mL

5.4143 mL

10 mM

0.2707 mL

1.3536 mL

2.7072 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 50% PBS

Solubility: 5 mg/mL (13.54 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88. [Content Brief]

[2]. Alford VM, Kamath A, Ren X, et al. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol. 2017;12(11):2788-2803. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7072 mL	13.5358 mL	27.0717 mL	67.6791 mL
	5 mM	0.5414 mL	2.7072 mL	5.4143 mL	13.5358 mL
	10 mM	0.2707 mL	1.3536 mL	2.7072 mL	6.7679 mL
	15 mM	0.1805 mL	0.9024 mL	1.8048 mL	4.5119 mL
	20 mM	0.1354 mL	0.6768 mL	1.3536 mL	3.3840 mL
	25 mM	0.1083 mL	0.5414 mL	1.0829 mL	2.7072 mL
	30 mM	0.0902 mL	0.4512 mL	0.9024 mL	2.2560 mL
	40 mM	0.0677 mL	0.3384 mL	0.6768 mL	1.6920 mL
	50 mM	0.0541 mL	0.2707 mL	0.5414 mL	1.3536 mL
	60 mM	0.0451 mL	0.2256 mL	0.4512 mL	1.1280 mL
	80 mM	0.0338 mL	0.1692 mL	0.3384 mL	0.8460 mL
	100 mM	0.0271 mL	0.1354 mL	0.2707 mL	0.6768 mL

Bioz

Keywords

MMP-9-IN-1

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MMP-9-IN-1

SB-3CT

JNJ0966

ARP-100

MG-132

Ilomastat

Marimastat

Batimastat

Cordycepin

NSC 405020

Morroniside

Incyclinide

Bafilomycin A1

Publications Citing Use of MedChemExpress (MCE) MMP-9-IN-1

Alle MMP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

MMP-9-IN-1

SB-3CT

JNJ0966

ARP-100

MG-132

Ilomastat

Marimastat

Batimastat

Cordycepin

NSC 405020

Morroniside

Incyclinide

Bafilomycin A1

Publications Citing Use of MedChemExpress (MCE) MMP-9-IN-1

Alle MMP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MMP-9-IN-1 Related Classifications

HY-135232 Related Classifications

Bioz